Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the...
Full
Pyxis Oncology - Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201),...
Sutro Biopharma, Inc. – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management...
From a hydrating serum to a buildable concealer stickPureWow editors select every item that appears on this page, and some...
